Nykode Therapeutics

Carnegie Investment Bank congratulates Nykode Therapeutics on their uplisting of the Company’s shares to the main list of the Oslo Stock Exchange.
 
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.
 
Carnegie is proud to have acted as Joint Lead Manager in the uplisting, and wishes to thank Nykode for the vote of confidence.

Related articles

Cloudberry Clean Energy
Investment Banking

Cloudberry Clean Energy

Carnegie Investment Bank is proud to have acted as Joint Global Coordinator in connection with the...

Agilyx
Investment Banking

Agilyx

Carnegie Investment Bank is proud to have acted as Joint Bookrunner in connection with the NOK...

Holzweiler
Investment Banking

Holzweiler

Carnegie is proud to have acted as financial advisor to Holzweiler and its owners in connection with...